https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0050
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiovascular disease remains a leading cause of death and disability worldwide. Heart failure (HF) is the end stage of various cardiovascular diseases. Despite recent advancements in understanding of HF pathogenesis and treatment, the prognosis of patients with HF remains poor. Inflammation is a key player in the development of HF, and its role in the pathogenesis of HF has been extensively studied. Inflammation is associated with elevated HF risk and adverse prognosis. Targeting cardiac inflammation has been suggested as a promising treatment strategy for HF. However, almost all clinical trials on the anti-inflammatory treatment of HF have not indicated improved clinical outcomes, and some have reported deterioration of the condition, possibly because of limited understanding of the specific role of inflammation in HF. The summary of inflammatory mechanisms contributing to the pathogenesis of different HF types, current anti-inflammation therapies for HF, and the results of clinical trials could provide new perspectives for understanding and targeting the role of inflammation in HF through the development of effective clinical therapeutic strategies.
CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Mingze
Jiang Yu, Guoxiang Zhou and Yongzheng Guo et al. Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies. CVIA. 2025. Vol. 10(1). DOI: 10.15212/CVIA.2024.0050